- Report
- October 2022
- 68 Pages
Global
- Report
- November 2021
- 106 Pages
Global
From €4723EUR$4,950USD£4,018GBP
- Report
- July 2018
- 15 Pages
Global
- Report
- June 2018
- 15 Pages
Global
- Report
- April 2023
- 110 Pages
Global
From €4532EUR$4,750USD£3,856GBP
- Report
- April 2023
- 111 Pages
Global
From €4532EUR$4,750USD£3,856GBP
- Report
- October 2022
- 113 Pages
Global
From €4532EUR$4,750USD£3,856GBP
- Report
- April 2023
- 200 Pages
Global
From €3769EUR$3,950USD£3,206GBP
- Report
- April 2023
- 500 Pages
Global
From €3101EUR$3,250USD£2,638GBP
- Report
- October 2022
- 300 Pages
Global
From €3769EUR$3,950USD£3,206GBP
- Report
- September 2022
- 100 Pages
Global
From €2624EUR$2,750USD£2,232GBP
- Drug Pipelines
- July 2022
- 100 Pages
Global
From €2624EUR$2,750USD£2,232GBP
- Report
- July 2022
- 100 Pages
Global
From €2624EUR$2,750USD£2,232GBP
- Report
- January 2022
- 200 Pages
Global
From €7156EUR$7,500USD£6,088GBP
- Report
- January 2022
- 60 Pages
Global
From €3769EUR$3,950USD£3,206GBP
- Report
- January 2022
- 60 Pages
Global
From €3769EUR$3,950USD£3,206GBP
- Clinical Trials
- September 2021
- 60 Pages
Global
From €1908EUR$2,000USD£1,623GBP
- Report
- April 2020
- 75 Pages
Global
From €3769EUR$3,950USD£3,206GBP
- Report
- March 2022
- 283 Pages
Global
From €4675EUR$4,900USD£3,977GBP
- Report
- November 2023
- 90 Pages
France
From €3340EUR$3,500USD£2,841GBP
CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells.
CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors.
CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more